| 6.11 0.095 (1.58%) | 10-03 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 7.81  |
1-year : | 8.86 |
| Resists | First : | 6.69 |
Second : | 7.59 |
| Pivot price | 6.31 |
|||
| Supports | First : | 5.23 |
Second : | 4.35 |
| MAs | MA(5) : | 6.65  |
MA(20) : | 6.26 |
| MA(100) : | 4.64 |
MA(250) : | 4.85 |
|
| MACD | MACD : | 0.2 |
Signal : | 0.3 |
| %K %D | K(14,3) : | 28.2 |
D(3) : | 55 |
| RSI | RSI(14): 50.3 |
|||
| 52-week | High : | 7.76 | Low : | 2.59 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ DSGN ] has closed above bottom band by 38.4%. Bollinger Bands are 58.2% wider than normal. The large width of the bands suggest high volatility as compared to its normal range. The bands have been in this wide range for 3 days. This is a sign that the current trend might continue.
| If tomorrow: | Open lower | Open higher |
| High: | 6.21 - 6.24 | 6.24 - 6.27 |
| Low: | 5.94 - 5.97 | 5.97 - 6 |
| Close: | 6.06 - 6.11 | 6.11 - 6.16 |
Design Therapeutics, Inc. a preclinical-stage biopharmaceutical company, engages in the development of therapies for the treatment of genetic diseases caused by nucleotide repeat expansions. The company's portfolio of products comprises Friedreich Ataxia, a monogenic, autosomal recessive, progressive multi-system disease that affects organ systems dependent on mitochondrial function, eventually leading to neurological, cardiac, and metabolic dysfunction; and Myotonic Dystrophy Type-1 (DM1), a dominantly-inherited, monogenic progressive neuromuscular disease affecting skeletal muscle, heart, brain, and other organs. It is also developing GeneTAC product candidate portfolio for the treatment of other nucleotide repeat expansion-driven monogenic diseases, such as Fragile X syndrome, spinocerebellar ataxias, amyotrophic lateral sclerosis, frontotemporal dementia, Huntington disease, and spinobulbar muscular atrophy. Design Therapeutics, Inc. was incorporated in 2017 and is headquartered in Carlsbad, California.
Mon, 29 Sep 2025
Design Therapeutics, Inc. $DSGN Shares Sold by Assenagon Asset Management S.A. - Defense World
Thu, 11 Sep 2025
Design Therapeutics Appoints Justin Gover as Director - The Globe and Mail
Wed, 10 Sep 2025
Design Therapeutics Appoints Justin Gover to Board of Directors - The Globe and Mail
Wed, 10 Sep 2025
$7B GW Pharma Exit Veteran Justin Gover Joins Design Therapeutics Board to Advance Genetic Disease Pipeline - Stock Titan
Wed, 27 Aug 2025
Clinical-Stage Biotech Design Therapeutics to Share Updates at 2025 Cantor Healthcare Conference in NYC - Stock Titan
Wed, 04 Jun 2025
Design Therapeutics Achieves First Patient Dosing in Friedreich Ataxia Trial, Faces FDA Hurdle - Stock Titan
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 57 (M) |
| Shares Float | 23 (M) |
| Held by Insiders | 35.9 (%) |
| Held by Institutions | 63 (%) |
| Shares Short | 3,680 (K) |
| Shares Short P.Month | 3,510 (K) |
| EPS | -1.13 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.74 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -19.1 % |
| Return on Equity (ttm) | -26.8 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -0.79 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.31 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -51 (M) |
| Levered Free Cash Flow | -30 (M) |
| PE Ratio | -5.46 |
| PEG Ratio | 0 |
| Price to Book value | 1.63 |
| Price to Sales | 0 |
| Price to Cash Flow | -6.88 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|